EGFR D770_N771insGL

CI-VAR-00000540Explore in graph →NP_005219.2:p.Asp770_Asn771insGlyLeuNM_005228.3:c.2310_2311insGGGTTAClinVar 45257 CIViC 1514 rs397517111

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR D770_N771insGL	Erlotinib	Predictive	C	Supports Resistance	4	accepted	EID4494 2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib. A 45 year old male never smoker had progressive disease as best response with +24% change to tar… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
45257	Pathogenic	no assertion criteria provided	0	Non-small cell lung carcinoma	somatic	1	Jul 17, 2009	clinvar